Oncology

Pharmacists play a crucial role in evaluating 505(b)(2) drugs—from ensuring oncology therapeutic equivalence to improving access and outcomes.

Pharmacy Times interviewed Kimlin Ashing and Narissa Nonzee about their work examining how housing status, race, and ethnicity drive cancer screening disparities.

Enrique Velazquez Villarreal, MD, PhD, used a conversational AI platform to unify microbiome, genomic, clinical, and social determinants of health data for colorectal cancer research.

Research presented at the American Association for Cancer Research Annual Meeting shows personalized mRNA vaccine immunotherapy targets pancreatic cancer tumor neoantigens, sparking durable T-cell responses and boosting survival in a phase 1 clinical trial.

Oncology teams can address AI-driven cancer cures with empathy, evidence, and safer next steps to protect patients and trust.

EPCORE trial data show epcoritamab plus lenalidomide and rituximab delivers responses in relapsed/refractory follicular lymphoma with outpatient dosing.

Amber Clemmons PharmD, BCOP, FHOPA, highlights key changes in evidence grading, shared decision-making, and dosing strategies in neutropenia management.

Gwen Nichols shares her dream of changing the landscape of pediatric cancer research and care.

Adjuvant PD-1/PD-L1 inhibitors improve disease-free and metastasis-free survival in patients with solid tumors but require careful patient selection.

Pharmacist lung cancer insights on NSCLC: biomarker testing, PD-1 choices such as cemiplimab, and access tips for treating non–small cell lung cancer.

COVID-19 infection may create lasting changes in the lung microenvironment—particularly through thymidine phosphorylase–driven pathways—that could increase the risk of lung cancer over time.

WHI data link radon exposure to higher ovarian cancer risk and deaths; learn how home testing may reduce cancer risk in high-radon areas.

Emerging therapeutic options represent a new age for treatment of high-risk non–muscle invasive bladder cancer.

FDA fast track designation advances oral EP300/CBP inhibitor OPN-6602 for relapsed/refractory multiple myeloma, highlighting novel hematology-oncology options and key pharmacist considerations.

Students should consider reaching out to their experiential education department to learn what opportunities may be available.

Cristian Tomasetti, PhD, explains how obesity enlarges organs, raising cancer risk, and how GLP-1 weight loss therapy may reverse this, guiding oncology pharmacists.

In AML, sialylated CD43 blocks immune clearance beyond CD47, revealing new leukemia targets to boost macrophage phagocytosis.

TIL therapy offers a new metastatic melanoma option while FDA PDUFA dates reshape oncology approvals and planning.

This is the second complete response letter the manufacturer has received for this treatment regimen.

Keytruda Qlex is a subcutaneous formulation of pembrolizumab that offers a faster, more convenient alternative to IV administration with comparable efficacy.

Therapy-related acute myeloid leukemia (tAML) increases as cancer therapy improves, spotlighting AML risk after chemotherapy or radiation and the need for vigilant oncology monitoring.

ASCO guidelines reshape multiple myeloma care with quadruplet induction, earlier CAR T-cell therapy and bispecifics, and selective smoldering treatment.

Amy Seung outlines her priorities for leading HOPA through evolving therapies, workforce challenges, and expanding pharmacy roles.

Phase 3 trial data show that isatuximab quadruplet improves MRD negativity in transplant-eligible patients with multiple myeloma.

Pacritinib bridges high-risk myelofibrosis to allogeneic stem cell transplantation, preserving blood counts, shrinking spleen and symptoms, and enabling 95% of patients to undergo transplantation.